Kimberly A Chianese-Bullock

Summary

Affiliation: University of Virginia
Country: USA

Publications

  1. doi request reprint A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer
    Kimberly A Chianese-Bullock
    Department of Surgery, Division of Surgical Oncology, Human Immune Therapy Center, University of Virginia, Charlottesville, VA 22908, USA
    J Immunother 31:420-30. 2008
  2. ncbi request reprint Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells
    Craig L Slingluff
    Department of Surgery Division of Surgical Oncology, University of Virginia, Charlottesville, 22908, USA
    J Clin Oncol 21:4016-26. 2003
  3. ncbi request reprint Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2
    Kimberly A Chianese-Bullock
    Department of Surgery Division of Surgical Oncology, University of Virginia, Charlottesville, Virginia 22908, USA
    J Immunother 28:412-9. 2005
  4. ncbi request reprint Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule
    Craig L Slingluff
    Department of Surgery, Human Immune Therapy Center, University of Virginia Health System, Charlottesville, VA 22908, USA
    J Clin Oncol 22:4474-85. 2004
  5. pmc Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines
    Craig L Slingluff
    Department of Surgery Division of Surgical Oncology, University of Virginia, Charlottesville, VA 22908, USA
    J Immunother 33:630-8. 2010
  6. pmc Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens
    Craig L Slingluff
    Department of Surgery Division of Surgical Oncology, University of Virginia Health System, Charlottesville, VA 22908, USA
    J Clin Oncol 26:4973-80. 2008
  7. ncbi request reprint Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting
    Craig L Slingluff
    Department of Surgery, University of Virginia, Charlottesville, Virginia 22908, USA
    Clin Cancer Res 13:6386-95. 2007
  8. ncbi request reprint MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma
    Kimberly A Chianese-Bullock
    Department of Surgery Division of Surgical Oncology, University of Virginia Health System, Charlottesville, VA 22908, USA
    J Immunol 174:3080-6. 2005
  9. pmc Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines
    Craig L Slingluff
    Department of Surgery, Division of Surgical Oncology, University of Virginia, Charlottesville, VA 22908, USA
    Ann Surg Oncol 15:3538-49. 2008
  10. pmc Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial
    Craig L Slingluff
    Department of Surgery Division of Surgical Oncology, Department of Public Health Sciences, and Department of Medicine Division of Hematology Oncology, University of Virginia, Charlottesville, Virginia, USA
    Clin Cancer Res 15:7036-44. 2009

Collaborators

Detail Information

Publications23

  1. doi request reprint A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer
    Kimberly A Chianese-Bullock
    Department of Surgery, Division of Surgical Oncology, Human Immune Therapy Center, University of Virginia, Charlottesville, VA 22908, USA
    J Immunother 31:420-30. 2008
    ....
  2. ncbi request reprint Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells
    Craig L Slingluff
    Department of Surgery Division of Surgical Oncology, University of Virginia, Charlottesville, 22908, USA
    J Clin Oncol 21:4016-26. 2003
    ..To determine clinical and immunologic responses to a multipeptide melanoma vaccine regimen, a randomized phase II trial was performed...
  3. ncbi request reprint Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2
    Kimberly A Chianese-Bullock
    Department of Surgery Division of Surgical Oncology, University of Virginia, Charlottesville, Virginia 22908, USA
    J Immunother 28:412-9. 2005
    ..However, careful monitoring for autoimmune toxicities should be incorporated in future clinical studies incorporating low-dose IL-2...
  4. ncbi request reprint Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule
    Craig L Slingluff
    Department of Surgery, Human Immune Therapy Center, University of Virginia Health System, Charlottesville, VA 22908, USA
    J Clin Oncol 22:4474-85. 2004
    ....
  5. pmc Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines
    Craig L Slingluff
    Department of Surgery Division of Surgical Oncology, University of Virginia, Charlottesville, VA 22908, USA
    J Immunother 33:630-8. 2010
    ..Despite the necessarily retrospective nature of the analysis and limitations of multiple comparisons, our summary data support the use of IFA-VG as an adjuvant with multipeptide vaccines in melanoma patients...
  6. pmc Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens
    Craig L Slingluff
    Department of Surgery Division of Surgical Oncology, University of Virginia Health System, Charlottesville, VA 22908, USA
    J Clin Oncol 26:4973-80. 2008
    ..Source proteins for these peptides include MAGE proteins, MART-1/MelanA, gp100, and tyrosinase...
  7. ncbi request reprint Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting
    Craig L Slingluff
    Department of Surgery, University of Virginia, Charlottesville, Virginia 22908, USA
    Clin Cancer Res 13:6386-95. 2007
    ..Because melanomas commonly evade immune recognition by selective antigen loss, optimization of melanoma vaccines may require development of more complex multipeptide vaccines...
  8. ncbi request reprint MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma
    Kimberly A Chianese-Bullock
    Department of Surgery Division of Surgical Oncology, University of Virginia Health System, Charlottesville, VA 22908, USA
    J Immunol 174:3080-6. 2005
    ..Cancer-testis Ags are expressed in multiple types of cancer; thus the MAGE-A1(96-104) and MAGE-A10(254-262) peptides may be considered for inclusion in vaccines against cancers of other histologic types, in addition to melanoma...
  9. pmc Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines
    Craig L Slingluff
    Department of Surgery, Division of Surgical Oncology, University of Virginia, Charlottesville, VA 22908, USA
    Ann Surg Oncol 15:3538-49. 2008
    ....
  10. pmc Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial
    Craig L Slingluff
    Department of Surgery Division of Surgical Oncology, Department of Public Health Sciences, and Department of Medicine Division of Hematology Oncology, University of Virginia, Charlottesville, Virginia, USA
    Clin Cancer Res 15:7036-44. 2009
    ..It also assessed immunogenicity of administration in one versus two vaccine sites...
  11. pmc Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine
    Craig L Slingluff
    Department of Surgery, Human Immune Therapy Center, University of Virginia, Charlottesville, VA 22908, USA
    J Clin Oncol 29:2924-32. 2011
    ....
  12. pmc A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602)
    Craig L Slingluff
    Department of Surgery, Human Immune Therapy Center, University of Virginia, Charlottesville, Virginia, USA
    Clin Cancer Res 19:4228-38. 2013
    ..This multicenter randomized trial was designed to evaluate whether melanoma helper peptides augment cytotoxic T lymphocyte (CTL) responses to a melanoma vaccine and improve clinical outcome in patients with advanced melanoma...
  13. pmc Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide
    Elise P Salerno
    Division of Surgical Oncology, Department of Surgery, University of Virginia, Charlottesville, VA, USA
    Cancer Immunol Immunother 62:1149-59. 2013
    ....
  14. pmc The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides
    Rebecca C Harris
    Department of Surgery, University of Virginia, Charlottesville, VA 22908, USA
    J Immunother 35:78-88. 2012
    ..Further study of the physiology of the vaccine site microenvironment promises to identify opportunities for enhancing cancer vaccine efficacy by modulating immune activation and regulation at the site of vaccination...
  15. pmc Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47)
    Craig L Slingluff
    University of Virginia, Charlottesville, VA 22908, USA
    Clin Cancer Res 19:3611-20. 2013
    ..A CTEP-sponsored phase II trial was conducted to evaluate safety and clinical activity of combination therapy with CCI-779 (temsirolimus) and bevacizumab in patients with advanced melanoma...
  16. pmc The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines
    Donna H Deacon
    Department of Surgery, University of Virginia, Charlottesville, VA 22908, USA
    BMC Cancer 8:360. 2008
    ..We have, therefore, investigated ultraviolet (UV)-irradiation as a possible adjunct to, or replacement for gamma-irradiation...
  17. pmc Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function
    Walter C Olson
    Human Immune Therapy Center, University of Virginia, Charlottesville, VA, USA
    J Transl Med 9:26. 2011
    ..The effect of temperature during storage and shipment of peripheral blood on subsequent processing, recovery, and function of lymphocytes is understudied and represents the focus of this study...
  18. pmc Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies
    Kimberly A Chianese-Bullock
    Department of Surgery Division of Surgical Oncology Human Immune Therapy Center, University of Virginia, Charlottesville, VA 22908, United States
    Vaccine 27:1764-70. 2009
    ..Results from these analyses have implications for changing the way peptide-based vaccines are manufactured and demonstrate that multi-peptide vaccines are reliable reagents for use in peptide-based immune therapies...
  19. pmc Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma
    Geoffrey R Weiss
    Department of Medicine Division of Hematology Oncology, University of Virginia Health System, Charlottesville, 22908, USA
    Clin Cancer Res 17:7440-50. 2011
    ..These effects are independent of tumor response to treatment. Here, we prospectively evaluated transcriptional alterations induced by rIL-2 in peripheral blood mononuclear cells (PBMC) and within melanoma metastases...
  20. ncbi request reprint Usefulness of prestudy assessment of patient willingness to undergo tissue biopsy for correlative studies in a melanoma vaccine trial
    Joshua M Judge
    Department of Surgery, University of Virginia, Charlottesville, VA 22908, USA
    Clin Trials 10:143-50. 2013
    ..Performing biopsies for correlative studies in cancer trials raises ethical and regulatory concerns and may impact trial accrual negatively. However, strategies to address these concerns remain largely unexplored...
  21. ncbi request reprint Competition among peptides in melanoma vaccines for binding to MHC molecules
    Lee W Thompson
    Department of Surgery, Division of Surgical Oncology, University of Virginia Health System, Charlottesville, Virginia, USA
    J Immunother 27:425-31. 2004
    ..These data suggest that CTLs can respond to multiple peptides presented on the same antigen-presenting cells and justify further investigation, in clinical trials, of multiple-peptide cancer vaccines...
  22. ncbi request reprint Assessment of the toxicities of systemic low-dose interleukin-2 administered in conjunction with a melanoma peptide vaccine
    Elizabeth M H Woodson
    Department of Surgery Division of Surgical Oncology, University of Virginia, Charlottesville, Virginia 22908, USA
    J Immunother 27:380-8. 2004
    ..The hematologic effects of this therapy were delayed in time between the two treatment groups, without dramatic differences in magnitude, which suggests minimal modulation of the IL-2 toxicity by components of the vaccine...
  23. pmc Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model
    Carolina Soguero
    Beirne Carter Center for Immunology Research, University of Virginia, Charlottesville, Virginia 22908, USA
    J Virol 76:9345-54. 2002
    ..These results suggest that HCV core drives liver injury by increasing Fas-mediated apoptosis and liver infiltration of peripheral T cells...